Pricing Log in Create free account

Crescent Biopharma, Inc. (CBIO) vs DiaMedica Therapeutics, Inc. (DMAC)

Crescent Biopharma, Inc. and DiaMedica Therapeutics, Inc. are both Biotechnology companies. Crescent Biopharma, Inc. and DiaMedica Therapeutics, Inc. are of similar size ($487.5M and $480.6M). Across the 9 metrics below, Crescent Biopharma, Inc. leads on 7 and DiaMedica Therapeutics, Inc. on 2.

Valuation

Metric CBIO DMAC Biotechnology median
P/E n/m n/m 10.60
P/S 337.85 n/m 9.40
P/B 2.58 13.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 227.76 n/m 9.02
Earnings yield (49.85%) (7.61%) (32.88%)
Free cash flow yield (17.46%) (6.19%) (23.13%)

Profitability

Metric CBIO DMAC Biotechnology median
Gross margin 19.72% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (101.95%) (114.62%) (51.96%)
Return on assets (88.26%) (98.18%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CBIO DMAC Biotechnology median
Revenue growth (TTM) (45.09%) — 6.76%
EPS growth (last fiscal year) 78.20% (16.67%) 29.88%
Revenue growth, 5-year CAGR 257.77% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CBIO DMAC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.66 6.72 4.97
Net debt to EBITDA 1.40 1.70 1.01

Dividend

Metric CBIO DMAC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CBIO DMAC Biotechnology median
Market cap 480.64m 487.49m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack